TY - JOUR AU - Macura, Sherrill L. AU - Steinbacher, Jeremy L. AU - MacPherson, Maximilian B. AU - Lathrop, Melissa J. AU - Sayan, Mutlay AU - Hillegass, Jedd M. AU - Beuschel, Stacie L. AU - Perkins, Timothy N. AU - Spiess, Page C. AU - van der Vliet, Albert AU - Butnor, Kelly J. AU - Shukla, Arti AU - Wadsworth, Marilyn AU - Landry, Christopher C. AU - Mossman, Brooke T. PY - 2013 DA - 2013/09/11 TI - Microspheres targeted with a mesothelin antibody and loaded with doxorubicin reduce tumor volume of human mesotheliomas in xenografts JO - BMC Cancer SP - 400 VL - 13 IS - 1 AB - Malignant mesotheliomas (MMs) are chemoresistant tumors related to exposure to asbestos fibers. The long latency period of MM (30-40 yrs) and heterogeneity of tumor presentation make MM difficult to diagnose and treat at early stages. Currently approved second-line treatments following surgical resection of MMs include a combination of cisplatin or carboplatin (delivered systemically) and pemetrexed, a folate inhibitor, with or without subsequent radiation. The systemic toxicities of these treatments emphasize the need for more effective, localized treatment regimens. SN - 1471-2407 UR - https://doi.org/10.1186/1471-2407-13-400 DO - 10.1186/1471-2407-13-400 ID - Macura2013 ER -